GH Research $GHRS

Health Care · NASDAQ

$17.53
-1.03 (-5.55%)
As of Nov 20, 2026, 4:05 PM EST · cached
Price history
Loading chart…
Today's analyst average Analyst average over timeIndividual analyst targets Analyst history starts Nov 13, 2026, the first target we tracked for GHRS.

GH Research (GHRS) is trading down at $17.53 (-5.55%) on NASDAQ, as of the latest quote. It operates in the Health Care sector.

IPO: June 25, 2021 · $16.00 offering · NASDAQ

Analyst price targets on GHRS

One firm's current price target on GH Research: $38 — 117% above the current $17.5. Each is tracked to its date and scored the same way a member's call is.

1 target, newest first. Open a row for its source and scoring.

DateNov 13, 2026 FirmStifel RatingBuy · reiterates Targetat $19.1 · $38 +99% Horizonby Nov 2027 StatusOpen

Entry price $19.1, the close nearest Nov 13, 2026, when the target was reported; the target is +99% from it.

Horizon No horizon stated, so it is tracked over the 12-month default, to Nov 2027.

Scoring Open: judged on the close on Nov 13, 2027.

Source Stifel reiterates GH Research stock rating on FDA alignment Investing.com · Nov 13, 2026 · opens the publisher's site
Stifel reiterated a Buy rating and $38.00 price target on GH Research PLC

Targets published by research firms, extracted from the news, checked against independent reporting, and linked to their source. Where a firm did not state a horizon the target is tracked as 12 months, the industry convention; the rows where the firm set its own horizon are marked. “At” is the closing price nearest the day the target was reported, the price we score it from; it is not an earlier target. Reported here as facts about what was published — not recommendations from Dalsna Finance, and no firm listed is affiliated with this site.

GH Research net income history (FY2019–FY2025)

Net income
$0−$24.1M−$48.3MFY2019 net income: −$310.0K'19FY2020 net income: −$446.0K'20FY2021 net income: −$9.20M'21FY2022 net income: −$22.5M'22FY2023 net income: −$35.6M'23FY2024 net income: −$39.0M'24FY2025 net income: −$48.3M'25
GH Research annual financial statements
FY2019Dec 2019FY2020Dec 2020FY2021Dec 2021FY2022Dec 2022FY2023Dec 2023FY2024Dec 2024FY2025Dec 2025
Income statement
Operating income−$310.0K−$446.0K−$15.1M−$30.6M−$41.2M−$50.3M−$60.7M
Net income−$310.0K−$446.0K−$9.20M−$22.5M−$35.6M−$39.0M−$48.3M
EPS (diluted)−$0.01−$0.02−$0.21−$0.43−$0.68−$0.75−$0.79
Balance sheet
Cash and equivalents$498.0K$5.89M$276.8M$166.0M$78.4M$100.8M$246.3M
Total assets—$5.91M$279.9M$254.4M$226.3M$188.3M$288.2M
Total liabilities—$246.0K$2.75M$4.55M$7.33M$9.32M$8.53M
Shareholders' equity$400.0K$5.67M$277.2M$249.8M$219.0M$179.0M$279.7M
Cash flow
Operating cash flow−$289.0K−$330.0K−$15.3M−$26.2M−$33.3M−$42.3M−$43.6M
Capital expenditure$0$0$104.0K$67.0K$100.0K$49.0K$121.0K
Free cash flow−$289.0K−$330.0K−$15.4M−$26.3M−$33.4M−$42.3M−$43.7M

From GH Research's 20-F and 6-K filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. Per-share figures are per ordinary share, which is not always the share traded in the US: an ADS can stand for several, or for part of one. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →

GH Research in the news

Nov 18, 2026 Investing.com Guggenheim raises GH Research stock price target to $46 on pivotal trial progress
Nov 13, 2026 Investing.com Stifel reiterates GH Research stock rating on FDA alignment Target
Nov 13, 2026 Investing.com GH Research names Vanina Popova as chief development officer
Nov 13, 2026 GlobeNewswire GH Research Reports Third Quarter 2026 Financial Results and Provides Business Update
Nov 13, 2026 GlobeNewswire GH Research Announces Appointment of Vanina Popova, MD, as Chief Development Officer
Show 1 older story
Sep 11, 2026 Stock Titan GH Research (GHRS) plans one-on-one talks at 2026 Morgan Stanley healthcare event

About GH Research

Headquarters
Dublin, Ireland From SEC filings, Oct 2026

More Health Care stocks

Browse all companies →